- Home
- RLAY vs TECH Comparison
RLAY vs TECH Comparison
Compare RLAY & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- TECH
- Stock Information
- Founded
- RLAY 2015
- TECH 1976
- Country
- RLAY United States
- TECH United States
- Employees
- RLAY N/A
- TECH N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RLAY Health Care
- TECH Health Care
- Exchange
- RLAY Nasdaq
- TECH Nasdaq
- Market Cap
- RLAY 576.1M
- TECH 7.8B
- IPO Year
- RLAY 2020
- TECH 1989
- Fundamental
- Price
- RLAY $3.63
- TECH $53.14
- Analyst Decision
- RLAY Strong Buy
- TECH Buy
- Analyst Count
- RLAY 11
- TECH 11
- Target Price
- RLAY $18.40
- TECH $72.00
- AVG Volume (30 Days)
- RLAY 1.6M
- TECH 2.2M
- Earning Date
- RLAY 08-05-2025
- TECH 08-06-2025
- Dividend Yield
- RLAY N/A
- TECH 0.60%
- EPS Growth
- RLAY N/A
- TECH N/A
- EPS
- RLAY N/A
- TECH 0.83
- Revenue
- RLAY $7,679,000.00
- TECH $1,208,770,000.00
- Revenue This Year
- RLAY $14.31
- TECH $7.07
- Revenue Next Year
- RLAY N/A
- TECH $5.64
- P/E Ratio
- RLAY N/A
- TECH $64.02
- Revenue Growth
- RLAY N/A
- TECH 4.72
- 52 Week Low
- RLAY $1.78
- TECH $46.01
- 52 Week High
- RLAY $10.72
- TECH $83.62
- Technical
- Relative Strength Index (RSI)
- RLAY 63.22
- TECH 59.96
- Support Level
- RLAY $3.10
- TECH $49.89
- Resistance Level
- RLAY $3.75
- TECH $53.95
- Average True Range (ATR)
- RLAY 0.23
- TECH 1.89
- MACD
- RLAY 0.03
- TECH 0.30
- Stochastic Oscillator
- RLAY 84.42
- TECH 85.38
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.